See more : Cipherlab Co.,Ltd. (6160.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Precigen, Inc. (PGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TZ Limited (TZL.AX) Income Statement Analysis – Financial Results
- Simplex Papers Limited (SIMPLXPAP.BO) Income Statement Analysis – Financial Results
- Lam Research Corporation (LRCX) Income Statement Analysis – Financial Results
- Natcore Technology Inc. (NTCXF) Income Statement Analysis – Financial Results
- PT Ciputra Development Tbk (CTRA.JK) Income Statement Analysis – Financial Results
Precigen, Inc. (PGEN)
About Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.23M | 26.91M | 103.87M | 103.18M | 90.72M | 160.57M | 230.98M | 190.93M | 173.61M | 71.93M | 23.76M | 13.93M | 8.01M |
| Cost of Revenue | 6.12M | 6.34M | 58.39M | 55.51M | 61.40M | 63.29M | 62.79M | 61.64M | 63.93M | 19.26M | 48.17M | 64.03M | 0.00 |
| Gross Profit | 106.00K | 20.57M | 45.49M | 47.67M | 29.32M | 97.29M | 168.19M | 129.29M | 109.68M | 52.67M | -24.41M | -50.11M | 8.01M |
| Gross Profit Ratio | 1.70% | 76.44% | 43.79% | 46.20% | 32.32% | 60.59% | 72.82% | 67.72% | 63.18% | 73.22% | -102.71% | -359.85% | 100.00% |
| Research & Development | 48.61M | 47.17M | 50.14M | 41.64M | 101.88M | 404.59M | 143.21M | 112.14M | 147.48M | 58.98M | 48.17M | 64.19M | 70.23M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.42M | 48.01M | 74.12M | 91.70M | 100.84M | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 18.30M |
| Other Expenses | 0.00 | 1.54M | -330.00K | -165.00K | 3.45M | 630.00K | 1.01M | 1.70M | 1.31M | -168.00K | -162.00K | -101.00K | -1.00K |
| Operating Expenses | 84.18M | 95.18M | 124.26M | 133.35M | 202.72M | 542.39M | 289.31M | 254.45M | 256.54M | 122.63M | 81.78M | 89.08M | 90.44M |
| Cost & Expenses | 95.15M | 101.52M | 182.65M | 188.86M | 264.12M | 605.68M | 352.10M | 316.09M | 320.47M | 141.89M | 81.78M | 89.08M | 90.44M |
| Interest Income | 3.24M | 133.00K | 1.62M | 2.45M | 3.87M | 19.08M | 19.49M | 10.19M | 1.88M | 806.00K | 166.00K | 5.00K | 0.00 |
| Interest Expense | 468.00K | 6.77M | 18.89M | 18.40M | 17.67M | 8.53M | 611.00K | 861.00K | 1.24M | 666.00K | 141.00K | 57.00K | 183.00K |
| Depreciation & Amortization | 6.67M | 7.19M | 8.14M | 15.04M | 16.14M | 24.11M | 31.15M | 24.57M | 17.74M | 10.42M | 7.21M | 7.98M | 4.34M |
| EBITDA | -89.23M | -66.00M | -84.07M | -70.41M | -137.46M | -349.06M | -97.94M | -168.72M | -67.99M | -74.64M | -33.56M | -73.83M | -80.76M |
| EBITDA Ratio | -1,433.35% | -267.84% | -74.60% | -81.93% | -185.73% | -272.15% | -49.75% | -70.39% | -87.91% | -103.69% | -247.44% | -485.08% | -974.54% |
| Operating Income | -88.92M | -74.61M | -78.78M | -85.68M | -173.40M | -505.61M | -137.89M | -125.17M | -146.86M | -69.96M | -58.02M | -75.16M | -82.43M |
| Operating Income Ratio | -1,428.48% | -277.25% | -75.84% | -83.04% | -191.14% | -314.88% | -59.70% | -65.56% | -84.60% | -97.26% | -244.20% | -539.73% | -1,028.67% |
| Total Other Income/Expenses | -7.44M | -5.36M | -19.56M | -18.35M | -35.29M | -26.25M | 17.80M | -68.99M | 59.89M | -15.76M | 17.12M | -6.72M | -2.85M |
| Income Before Tax | -96.36M | -79.97M | -96.93M | -103.86M | -208.69M | -536.23M | -129.70M | -194.15M | -86.98M | -85.72M | -40.91M | -81.87M | -85.28M |
| Income Before Tax Ratio | -1,547.98% | -297.17% | -93.31% | -100.66% | -230.03% | -333.95% | -56.15% | -101.69% | -50.10% | -119.17% | -172.17% | -587.96% | -1,064.27% |
| Income Tax Expense | -458.00K | -189.00K | -160.00K | -82.00K | -930.00K | -21.53M | -2.88M | -3.88M | 1.02M | -103.00K | -9.76M | -318.00K | 182.00K |
| Net Income | -95.90M | -79.78M | -96.77M | -103.77M | -207.76M | -509.34M | -117.02M | -186.61M | -84.49M | -81.82M | -38.98M | -81.87M | -85.28M |
| Net Income Ratio | -1,540.63% | -296.47% | -93.16% | -100.58% | -229.00% | -317.20% | -50.66% | -97.74% | -48.67% | -113.75% | -164.06% | -587.96% | -1,064.27% |
| EPS | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| EPS Diluted | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| Weighted Avg Shares Out | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
| Weighted Avg Shares Out (Dil) | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
Precigen Announces Proposed $30 Million Public Offering of Common Stock
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Source: https://incomestatements.info
Category: Stock Reports